NC/Nga 마우스에서 Dermatophagoides farinae의 피부 적용과 기도 유발에 의해 발생한 기도 염증에 대한 CpG Oligodeoxynucleotide의 효과
Effects of CpG Oligodeoxynucleotide on Airway Inflammation after Topical Application of and Airway Challenge with Dermatophagoides farinae in NC/Nga Mice
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Atopic dermatitis (AD) is the initial step of allergic march that progresses to airway allergic disease. There has been much interest in the interruption of the allergic march, but the results are not promising. CpG oligodeoxynucleotide (ODN) has been reported to have both preventive and therapeutic effects on the development of asthma in mouse models. Objective: To identify the development of airway inflammation after having atopic dermatitis-like skin lesions induced by topical application of Dermatophagoides farinae (Df), and to evaluate the preventive effect of CpG ODN on the development of airway inflammation. Method: We injected 5μg of Df intradermally 8 times for 2 weeks into 8-week-old NC/Nga mice and then challenged them with 3 times of Df intranasally. CpG ODN with or without Df was injected subcutaneously before airway challenge. Airway hyperreactivity was determined by the change inenhanced pause (Penh) during methacholine provocation. Lung tissue and bronchoalveolar lavage specimens were evaluated. Result: Topical Df application induced AD-like skin lesion microscopically, but not macroscopically. NC/Nga mice with topical Df application developed more severe airway inflammation upon intranasal Df challenge than those with topical PBS application. However, the mice with CpG ODN injection before airway challenge showed reduced airway inflammation. The levels of Df-specific IgG1 were increased in the mice with both topical Df application and intranasal Df challenge but were decreased in the mice with CpG ODN injection. Conclusion: These results suggest that CpG may inhibit the development of airway inflammation from those with previous AD-like skin lesions induced by Df.
Abstract
Background: Atopic dermatitis (AD) is the initial step of allergic march that progresses to airway allergic disease. There has been much interest in the interruption of the allergic march, but the results are not promising. CpG oligodeoxynucleotide (ODN) has been reported to have both preventive and therapeutic effects on the development of asthma in mouse models. Objective: To identify the development of airway inflammation after having atopic dermatitis-like skin lesions induced by topical application of Dermatophagoides farinae (Df), and to evaluate the preventive effect of CpG ODN on the development of airway inflammation. Method: We injected 5μg of Df intradermally 8 times for 2 weeks into 8-week-old NC/Nga mice and then challenged them with 3 times of Df intranasally. CpG ODN with or without Df was injected subcutaneously before airway challenge. Airway hyperreactivity was determined by the change inenhanced pause (Penh) during methacholine provocation. Lung tissue and bronchoalveolar lavage specimens were evaluated. Result: Topical Df application induced AD-like skin lesion microscopically, but not macroscopically. NC/Nga mice with topical Df application developed more severe airway inflammation upon intranasal Df challenge than those with topical PBS application. However, the mice with CpG ODN injection before airway challenge showed reduced airway inflammation. The levels of Df-specific IgG1 were increased in the mice with both topical Df application and intranasal Df challenge but were decreased in the mice with CpG ODN injection. Conclusion: These results suggest that CpG may inhibit the development of airway inflammation from those with previous AD-like skin lesions induced by Df.
참고문헌 (20)
- Tao Zheng, "The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma", Allergy, Asthma & Immunology Research, 3(2), pp.67~73 (2011), 대한천식알레르기학회
- Warner JO, "Early Treatment of the Atopic Child. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up", J Allergy Clin Immunol, 108, pp.929~937 (2001)
- Simons FE, "Safety of levocetirizine treatment in young atopic children: An 18-month study", Pediatr Allergy Immunol, 18, pp.535~542 (2007)
- Spergel JM, "From atopic dermatitis to asthma: the atopic march", Ann Allergy Asthma Immunol, 105, pp.99~106 (2010)
- Spergel JM, "Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice", J Clin Invest, 101, pp.1614~1622 (1998)
- He R, "Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13", J Allergy Clin Immunol, 124, pp.761~770.e1 (2009)
- Tighe H, "Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity", J Allergy Clin Immunol, 106, pp.124~134 (2000)
- Ikeda RK, "Resolution of airway inflammation following ovalbumin inhalation: comparison of ISS DNA and corticosteroids", Am J Respir Cell Mol Biol, 28, pp.655~663 (2003)
- Inoue J, "Suppression of skin lesions by transdermal application of CpG-oligodeoxynucleotides in NC", Nga mice, a model of human atopic dermatitis, 2007, pp.178, 584~591
- Mo JH, "Suppression of allergic response by CpG motif oligodeoxynucleotide- house-dust mite conjugate in animal model of allergic rhinitis", Am J Rhinol, 20, pp.212~218 (2006)
- 김태윤, "Effect of Dendritic Cells Treated with CpG ODNon Atopic Dermatitis of Nc", Nga mice, 2007, pp.40(4), 486~493[DOI]
- Creticos PS, "Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis", N Engl J Med, 355, pp.1445~1455 (2006)
- Fonseca DE, "Use of CpG oligonucleotides in treatment of asthma and allergic disease", Adv Drug Deliv Rev, 61, pp.256~262 (2009)
- LaRosa DF, "CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells", Immunol Lett, 108, pp.183~188 (2007)
- Wang G, "Immunostimulatory sequence CpG elicits Th1-type immune responses in inflammatory skin lesions in an atopic dermatitis murine model", Int Arch Allergy Immunol, 147, pp.41~51 (2008)
- Shiohara T, "Animal models for atopic dermatitis: are they relevant to human disease", J Dermatol Sci, 36, pp.1~9 (2004)
- Platts-Mills TA, "Dust mites: immunology, allergic disease, and environmental control", J Allergy Clin Immunol, 80, pp.755~775 (1987)
- Sasakawa T, "Atopic dermatitis-like skin lesions induced by topical application of mite antigens in NC", Nga mice, 2001, pp.126, 239~247
- Clark RA, "Aeroallergen contact can exacerbate atopic dermatitis: patch tests as a diagnostic tool", J Am Acad Dermatol, 21, pp.863~869 (1989)
- He R, "Epicutaneous antigen exposure induces a Th17 response that drives airway inflammation after inhalation challenge", Proc Natl Acad Sci USA, 104, pp.15817~15822 (2007)